A detailed history of Raymond James Financial Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 283,476 shares of ACRS stock, worth $714,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares
283,476
Previous 277,259 2.24%
Holding current value
$714,359
Previous $393,000 36.9%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$1.41 - $2.13 $8,765 - $13,242
6,217 Added 2.24%
283,476 $538,000
Q2 2025

Aug 14, 2025

BUY
$1.08 - $1.63 $28,570 - $43,120
26,454 Added 10.55%
277,259 $393,000
Q1 2025

May 13, 2025

BUY
$1.53 - $2.6 $147,574 - $250,780
96,454 Added 62.49%
250,805 $383,000
Q4 2024

Feb 06, 2025

BUY
$1.15 - $4.59 $177,503 - $708,471
154,351 New
154,351 $382,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $168M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.